Integra LifeSciences Holdings (IART) 2018年年度报告「NASDAQ」.pdf

1、2018 Annual ReportTO OUR SHAREHOLDERSIn 1989,Dr.Richard Caruso had a vision to expand access to promising technology that enabled the human body to regenerate damaged or diseased tissues.Through his vision and persistence,he founded Integra LifeSciences and revolutionized the field of regenerative m

2、edicine,giving burn victims hope where it did not exist.Under the leadership of Stuart Essig,the company further expanded the use of this technology to other areas such as dural and nerve repair.Thirty years later,Integra LifeSciences has become a global leader in regenerative medicine and neurosurg

3、ery.Every day,4,500 Integra colleagues continue to bring hope to patients around the world through our broad portfolio of innovative medical technologies and products for wound care,surgical reconstruction,neurosurgery and extremity orthopedics.For the fifth consecutive year,Integra delivered double

4、-digit revenue and adjusted earnings per share growth.Total revenues increased 24 percent to$1.47 billion and adjusted earnings per share increased 25 percent to$2.42.We generated nearly$200 million of operating cash and over$120 million in free cash flow,both of which were records for the company.W

5、e significantly strengthened our capital structure,providing additional flexibility to support our long-term strategic plans.Our Codman Specialty Surgical business grew 33.8 percent to nearly$964 million in reported sales versus the prior year,while organic sales increased 3.4 percent.This growth wa

6、s driven by the Codman Neurosurgery acquisition,continued strength of our CUSA Clarity Ultrasonic Tissue Ablation System,and growth in our dural access and repair franchise.Orthopedics and Tissue Technologies revenues were$508 million dollars,representing an increase of 8.7 percent on a reported bas